(CercleFinance.com) – The group presents breakthrough phase III data presented at the 2022 EADV Congress showing that Dupixent® (dupilumab) significantly improves the signs and symptoms of nodular prurigo.
At 24 weeks, almost three times as many patients treated with Dupixent experienced a clinically significant decrease in itching and skin lesions compared to those treated with placebo.
‘There are currently no drugs specifically approved for the treatment of nodular prurigo; the request for approval in the United States is given priority review; the request for approval in the European Union is under review, ‘says the group.
The group will present 22 abstracts on Dupixent at the 2022 Congress of the European Academy of Dermatology and Venereology (EADV, European Academy of Dermatology and Venereology) on four dermatological diseases bearing a type 2 inflammatory signature.